A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

  • days left to enroll
  • participants needed
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 6 June 2022


The goal of this trial is to test the safety and efficacy of an innovative combination aimed to more profoundly inhibit ERK signaling in tumors.

Condition Advanced BRAF Mutant Cancers
Treatment Binimetinib, Encorafenib
Clinical Study IdentifierNCT03843775
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on6 June 2022


Yes No Not Sure

Inclusion Criteria

Patient has signed the Informed Consent (ICF) prior to any screening procedures being performed and is able to comply with protocol requirements
Age ≥ 18 years at the time of informed consent
Metastatic or advanced-stage malignant tumors confirmed histologically for whom no standard therapy is considered to be appropriate by the investigator
Patients must have at least one other lesion that is measurable by RECIST criteria
Patient's tumor must harbor an activating BRAF mutation (listed in Table 4 or approved by the study Principal Investigator) or a fusion involving the kinase domain of BRAF
Mechanistically validated activating non-V600 BRAF mutants
BRAF kinase duplication
Fusions involving BRAF kinase domain
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
Adequate bone marrow, organ function and laboratory parameters
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
Hemoglobin (Hgb) ≥ 8 g/dL with or without transfusions
Platelets (PLT) ≥ 75 x 109/L without transfusions
AST and/or ALT ≤ 2.5 × upper limit of normal (ULN); patient with liver metastases ≤ 5 ×ULN
Total bilirubin ≤ 1.5 × ULN and < 2 mg/dL (Note: Patients who have a total bilirubin level > 1.5 x ULN will be allowed if their indirect bilirubin level is ≤ 1.5 x ULN)
Serum Creatinine ≤ 1.5 x ULN, or calculated creatinine clearance (determined as per Cockcroft-Gault) ≥ 50 mL/min at screening
Adequate cardiac function
left ventricular ejection fraction (LVEF) ≥ 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram
QTc interval ≤ 480 ms (preferably the mean from triplicate ECGs)
Able to take oral medications
Patient is deemed by the Investigator to have the initiative and means to be compliant with the protocol (treatment and follow-up)
Female patients are either postmenopausal for at least 1 year, are surgically sterile for at least 6 weeks, or must agree to take appropriate precautions to avoid pregnancy from screening through 30 days after the last dose of study drug/treatmentif of childbearing potential (Note: Permitted contraception methods listed in Section 9.3 should be communicated to the patients and their understanding confirmed. For females of childbearing potential, the pregnancy test result must be negative at screening.)
Males must agree to take appropriate precautions to avoid fathering a child from screening through 90 days following the end of therapy. (Note: Permitted contraception methods listed in Section 9.3 should be communicated to the patients and their understanding confirmed.)

Exclusion Criteria

Any symptomatic brain metastasis (Note: Patients previously treated or untreated for this condition who are asymptomatic in the absence of corticosteroid and antiepileptic therapy are allowed. Brain metastases must be stable for ≥ 4 weeks, with imaging (e.g., magnetic resonance imaging [MRI] or computed tomography [CT]) demonstrating no current evidence of progressive brain metastases at screening.)
History or current evidence of retinal vein occlusion (RVO) or current risk factors to RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes); history of retinal degenerative disease
Leptomeningeal disease
Previous or concurrent malignancy within 2 years of study entry, with the following exceptions: adequately treated basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, early stage breast cancer, or other noninvasive or indolent malignancy
Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following
History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) < 6 months prior to screening
Symptomatic chronic heart failure (i.e. Grade 2 or higher), history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality < 6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia
Uncontrolled hypertension defined as persistent elevation of systolic blood pressure ≥
mmHg or diastolic blood pressure ≥ 100 mmHg, despite current therapy
Known positive serology for HIV (Human Immunodeficiency Virus), active hepatitis B, and/or active hepatitis C infection
Impaired GI function or disease that may significantly alter the absorption of encorafenib or binimetinib (e.g., ulcerative diseases, uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption)
History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to the first dose of study treatment. Examples include transient ischemic attacks, cerebrovascular accidents, hemodynamically significant (i.e. massive or sub-massive) deep vein thrombosis or pulmonary emboli
Note: Patients with either deep vein thrombosis or pulmonary emboli that does not result in
hemodynamic instability are allowed to enroll as long as they are on a stable dose of
anticoagulants for at least 4 weeks. Note: Patients with thromboembolic events related to
indwelling catheters or other procedures may be enrolled.Concurrent neuromuscular disorder
that is associated with the potential of elevated CK (e.g., inflammatory myopathies
muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy)
Any other condition that would, in the Investigator's judgement, contraindicate the
patient's participation in the clinical study due to safety concerns or compliance
with clinical study procedures, e.g., infection/inflammation, intestinal obstruction
unable to swallow medications, social/psychological issues, etc
Patients who have undergone surgery ≤ 3 weeks prior to starting study drug or who have
not yet recovered from side effects of such procedure
Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
female after conception and until the termination of gestation, confirmed by a
positive hCG laboratory test
Medical, psychiatric, cognitive, or other conditions that may compromise the patient's
ability to understand the patient information, give informed consent, comply with the
study protocol or complete the study
Prior treatment with any RAF, MEK, or ERK inhibitors (such as vemurafenib, dabrafenib
encorafenib; trametinib, cobimetinib, binimetinib, selumetinib; or BVD-523
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note